Treatment of multiple sclerosis with interferon beta-1 b.

Treatment of multiple sclerosis with interferon beta-1 b.

Detalhes bibliográficos
Principais autores:	Abdul-Ahad, A, Shah, S, Galazka, A
Formato:	Journal article
Idioma:	English
Publicado em:	1997

Registros relacionados

Treatment of multiple sclerosis with interferon beta-1b - Reply
por: Sibley, W, et al.
Publicado em: (1997)

Interferon beta treatment of multiple sclerosis.
por: Markovitz, D
Publicado em: (1994)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
por: Sibley, W, et al.
Publicado em: (1994)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
por: Damiano Paolicelli, et al.
Publicado em: (2009-07-01)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
por: Slobodan M Jankovic
Publicado em: (2010-03-01)

Beta-interferons in multiple sclerosis
por: Aggarwal Sourabh, et al.
Publicado em: (2010-01-01)

INTERFERON BETA-1B IN THE TREATMENT OF MULTIPLE-SCLEROSIS - FINAL OUTCOME OF THE RANDOMIZED CONTROLLED TRIAL
por: Duquette, P, et al.
Publicado em: (1995)

PHARMACOGENETICS OF INTERFERON BETA IN MULTIPLE SCLEROSIS
por: Mohamed Rayen Ganouni, et al.
Publicado em: (2023-10-01)

Twenty Years of Subcutaneous Interferon-Beta-1a for Multiple Sclerosis: Contemporary Perspectives
por: Mark S. Freedman, et al.
Publicado em: (2024-01-01)

Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
por: Mahe J, et al.
Publicado em: (2013-08-01)

PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
por: Reuss R
Publicado em: (2013-05-01)

16-year long-term follow-up of interferon beta-1b treatment in patients with multiple sclerosis
por: Ebers, G, et al.
Publicado em: (2005)

A COMPARATIVE ANALYSIS OF EFFICACY OF INTERFERON BETA 1-B AND NATALIZUMAB TREATMENT IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS
por: T. I. Yakushina, et al.
Publicado em: (2016-07-01)

INTERFERON BETA 1B FOR THE IMMUNOMODULATORY TREATMENT OF MULTIOCULAR SCLEROSIS IN PEDIATRIC NEUROLOGIC PRACTICES
por: O.V. Bykova, et al.
Publicado em: (2006-12-01)

INTERFERON BETA 1B FOR THE IMMUNOMODULATORY TREATMENT OF MULTIOCULAR SCLEROSIS IN PEDIATRIC NEUROLOGIC PRACTICES
por: O.V. Bykova, et al.
Publicado em: (2006-12-01)

Influence of Interferon beta treatment on quality of life in multiple sclerosis patients
por: De Caro Maria, et al.
Publicado em: (2006-12-01)

Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis
por: Ivanović Jovana, et al.
Publicado em: (2019-01-01)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
por: Cocco E, et al.
Publicado em: (2015-05-01)

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
por: Castrop F, et al.
Publicado em: (2013-09-01)

Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis
por: Éric Toussirot, et al.
Publicado em: (2014-01-01)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Làzaro Aurelio Vàzquez Gòmez, et al.
Publicado em: (2022-10-01)

Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis
por: A.L. Guerrero, et al.
Publicado em: (2011-01-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
por: Petkau, A, et al.
Publicado em: (2004)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Alexandre Xavier, et al.
Publicado em: (2023-05-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
por: Petkau, A, et al.
Publicado em: (2004)

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
por: Duquette, P, et al.
Publicado em: (1996)

Safety of Use of Russian Biosimilars of Interferon Beta-1b in the Treatment of Multiple Sclerosis: a Meta-analysis of Original Studies
por: D. O. Gudz, et al.
Publicado em: (2019-06-01)

Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis
por: E Gibbons, et al.
Publicado em: (2015-01-01)

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
por: Parry, A, et al.
Publicado em: (2003)

beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis
por: Parry, A, et al.
Publicado em: (2002)

Effects of atorvastatin on some inflammatory markers in patients with multiple sclerosis treated by interferon beta-1b
por: Farah Waleed Mahmood, et al.
Publicado em: (2019-06-01)

SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodology
por: Mattle Heinrich P, et al.
Publicado em: (2009-12-01)

Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials
por: Yamaguchi Takuhiro, et al.
Publicado em: (2011-05-01)

A Case Report of Vasculitis Necrotizing after Interferon beta-1b Injection in Multiple Sclerosis
por: Mehrdokht Mazdeh
Publicado em: (2005-09-01)

The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis
por: Ebers, G, et al.
Publicado em: (1997)

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
por: Miraç Ayşen Ünsal
Publicado em: (2019-03-01)

Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis
por: Marco Aurélio Lana-Peixoto, et al.
Publicado em: (2002-09-01)

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis
por: Sørensen, P, et al.
Publicado em: (2010)

A cost-utility analysis of interferon beta for multiple sclerosis.
por: Parkin, et al.
Publicado em: (1998-01-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Masoud Mohammad Malekzadeh, et al.
Publicado em: (2020-06-01)